Tunneled Catheter-Related Bloodstream Infections in Chronic Hemodialysis Patients: Frequency, Risk Factors, and Outcomes—A 10-Year Analysis

IF 2.2 4区 医学 Q4 IMMUNOLOGY
Apmis Pub Date : 2025-03-13 DOI:10.1111/apm.70016
Mustafa Arslan, Ercan Kahraman, Elif Menekşe
{"title":"Tunneled Catheter-Related Bloodstream Infections in Chronic Hemodialysis Patients: Frequency, Risk Factors, and Outcomes—A 10-Year Analysis","authors":"Mustafa Arslan,&nbsp;Ercan Kahraman,&nbsp;Elif Menekşe","doi":"10.1111/apm.70016","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>The aim of this study is to investigate the rate, risk factors, causative microorganism distribution, and treatment outcomes of catheter-related bloodstream infection (CRBSI) in chronic hemodialysis patients undergoing treatment with a tunneled hemodialysis catheter. Data for all patients who underwent hemodialysis treatment with tunneled catheters at our center between January 2014 and January 2024 were retrospectively analyzed. A total of 171 patients were included in the study. Forty-five patients had 54 CRBSI episodes. The average time between catheter placement and the development of CRBSI was 127.4 days, and the risk of developing CRBSI increased as this duration extended. In the bivariate logistic regression analysis, advanced age (<i>p</i> = 0.03), diabetes (<i>p</i> = 0.005), duration of hemodialysis (<i>p</i> &lt; 0.001), decompensated cirrhosis (<i>p</i> = 0.02), and the femoral vein being the entry site (<i>p</i> = 0.011) were identified as risk factors for CRBSI. In the ROC analysis, the hemoglobin A1c threshold value for the development of CRBSI in diabetic patients was determined to be 9.350 (69% sensitivity, 87% specificity, AUC = 0.755, <i>p</i> &lt; 0.001). We believe that avoiding femoral vein catheterization as much as possible and expediting the transition from catheter to another method for dialysis are important measures to prevent the development of CRBSI.</p>\n </div>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"133 3","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Apmis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apm.70016","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The aim of this study is to investigate the rate, risk factors, causative microorganism distribution, and treatment outcomes of catheter-related bloodstream infection (CRBSI) in chronic hemodialysis patients undergoing treatment with a tunneled hemodialysis catheter. Data for all patients who underwent hemodialysis treatment with tunneled catheters at our center between January 2014 and January 2024 were retrospectively analyzed. A total of 171 patients were included in the study. Forty-five patients had 54 CRBSI episodes. The average time between catheter placement and the development of CRBSI was 127.4 days, and the risk of developing CRBSI increased as this duration extended. In the bivariate logistic regression analysis, advanced age (p = 0.03), diabetes (p = 0.005), duration of hemodialysis (p < 0.001), decompensated cirrhosis (p = 0.02), and the femoral vein being the entry site (p = 0.011) were identified as risk factors for CRBSI. In the ROC analysis, the hemoglobin A1c threshold value for the development of CRBSI in diabetic patients was determined to be 9.350 (69% sensitivity, 87% specificity, AUC = 0.755, p < 0.001). We believe that avoiding femoral vein catheterization as much as possible and expediting the transition from catheter to another method for dialysis are important measures to prevent the development of CRBSI.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Apmis
Apmis 医学-病理学
CiteScore
5.20
自引率
0.00%
发文量
91
审稿时长
2 months
期刊介绍: APMIS, formerly Acta Pathologica, Microbiologica et Immunologica Scandinavica, has been published since 1924 by the Scandinavian Societies for Medical Microbiology and Pathology as a non-profit-making scientific journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信